On November 25, 2024 Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, reported that members of senior management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 9:00 a.m. ET (Press release, Tempest Therapeutics, NOV 25, 2024, View Source [SID1234648620]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the live or archived recording of the discussion, please visit the investor section of the Tempest website at View Source

On November 25, 2024 Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, reported that it will webcast its presentations at two investor conferences in December (Press release, Sana Biotechnology, NOV 25, 2024, View Source [SID1234648619]). The presentations will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Sana will participate on a panel at Citi’s 2024 Global Healthcare Conference at 2:30 p.m. ET on Tuesday, December 3, 2024.
Sana will present at the 7th Annual Evercore ISI HealthCONx Conference at 2:35 p.m. ET on Wednesday, December 4, 2024.
The webcasts will be accessible on the Investor Relations page of Sana’s website at View Source A replay of each presentation will be available at the same location for 30 days following the conference.

On November 25, 2024 Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, reported a proposed public offering of $125 million of shares of its common stock and pre-funded warrants to purchase shares of common stock (Press release, Replimune, NOV 25, 2024, View Source [SID1234648618]). All securities in the offering will be offered by Replimune. In addition, Replimune intends to grant the underwriter a 30-day option to purchase up to an additional $18.75 million of securities from Replimune at the public offering price, less the underwriting discounts and commissions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Leerink Partners is acting as sole bookrunning manager for the proposed offering. The proposed offering is subject to market and other customary closing conditions, and Replimune cannot assure you as to whether or when the proposed offering may be completed.

The proposed offering will be made only by means of a preliminary prospectus supplement and the accompanying prospectus. A copy of the preliminary prospectus supplement and the accompanying prospectus relating to the proposed offering will be filed with the Securities and Exchange Commission (the "SEC") and may be obtained, when available, by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, copies of the preliminary prospectus supplement and the accompanying prospectus, when available, may be obtained from Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at (800) 808-7525, ext. 6105, or by email at [email protected]. The final terms of the proposed offering will be disclosed in a final prospectus supplement to be filed with the SEC.

The securities described above are being offered by Replimune pursuant to its shelf registration statement on Form S-3, including a base prospectus, that was previously filed by Replimune with the SEC on August 3, 2023, as amended by the Post-Effective Amendment No. 1 filed with the SEC on May 16, 2024 and as further amended by the Post-Effective Amendment No. 2 filed with the SEC on May 16, 2024, and declared effective by the SEC on July 22, 2024. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of securities, in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

On November 25, 2024 Rakovina Therapeutics Inc. (TSX-V: RKV) ("Rakovina" or the "Company"), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response targeting technologies, reported the presentation of a poster showcasing initial results of its Deep Docking Artificial Intelligence (AI) drug discovery screening at the 29th Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO), which was held November 21-24 in Houston, TX (Press release, Rakovina Therapeutics, NOV 25, 2024, View Source;utm_medium=rss&utm_campaign=rakovina-therapeutics-presents-ai-driven-drug-discovery-research-at-society-for-neuro-oncology-annual-meeting [SID1234648617]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster, titled "Utilizing Artificial Intelligence for the Discovery of Novel PARP1-Selective Inhibitors for Use Against Brain Tumors," highlighted a rapid virtual multi-billion compound screen to identify selective inhibitors of PARP-1, a key enzyme involved in DNA repair that plays a critical role in brain cancer progression. Inhibition of PARP-1 has shown promise in sensitizing cancer cells to treatment.

The poster provided insight into the compounds’ chemical properties affecting absorption, stability, and the ability to cross the blood-brain barrier. The poster also profiled candidates that are predicted to have similar or improved PARP-1 selectivity and central nervous system (CNS) exposure compared with AZD9574, a novel development-stage blood-brain barrier penetrant and selective inhibitor of PARP-1.

"Our team reached a significant milestone this fall with the initial results of our Deep Docking AI screening efforts, successfully evaluating billions of molecular structures within the projected timeframe described at the outset of the collaboration," said Jeffrey Bacha, Executive Chairman of Rakovina Therapeutics. "We were thrilled to present these preliminary findings to leading brain cancer researchers, clinicians, and potential pharmaceutical partners at the prestigious SNO conference. Our poster highlighted the transformative power of AI in accelerating the discovery of potential best-in-class drug candidates."

"Our innovative approach is not only improving the efficiency of drug discovery, but it is also enhancing the specificity and efficacy of potential therapeutics. Our novel class of PARP-1 selective inhibitors can offer hope for more effective treatments in the fight against primary brain tumors and cancers that have metastasized to the brain," he added. "The next step is to select a lead candidate molecule based on wet lab validation for target selectivity, metabolic and pharmacokinetic parameters, CNS penetration, and activity against cancer."

First-generation poly (ADP-ribose) polymerase (PARP) inhibitors have dramatically improved patient outcomes in certain mutated cancers but are limited in their utility to treat brain malignancies as they cannot pass through the blood-brain barrier. They also have adverse side effects that are possibly driven by the collateral inhibition of PARP-2. The successful development of a PARP-1 selective CNS penetrant inhibitor could reduce toxicity while providing a new therapeutic option for brain tumors.

Upcoming Video Conference Call

Rakovina Therapeutics will host a video conference call on Wednesday, November 27, 2024, at 10 am PST to further discuss the data presented at the Society for Neuro-Oncology Annual Meeting and discuss next steps and upcoming milestones in the PARP inhibitor and other development programs.

Register for the webinar or access the live stream here:

View Source

About the Society for Neuro-Oncology (SNO) Annual Meeting

The SNO Annual Meeting is the premier global event in neuro-oncology, bringing together over 2,600 researchers, clinicians, and scientists from more than 40 countries to advance the field of neuro-oncology. This influential conference features leading experts in oncology, providing a platform for the latest research, treatments, and innovations. The 2024 meeting took place at the George R. Brown Convention Center in Houston, Texas, from November 21-24. For more information, visit: View Source

On November 25, 2024 ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, reported that management will participate in the following investor conferences in December (Press release, ORIC Pharmaceuticals, NOV 25, 2024, View Source [SID1234648616]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

7th Annual Evercore HEALTHCONx Conference – Participating in a fireside chat on Wednesday, December 4, 2024, at 2:35 p.m. ET

Citi’s 2024 Global Healthcare Conference – Participating in the "Novel Mechanisms in Oncology II" panel on Thursday, December 5, 2024, at 11:00 a.m. ET

Live webcasts of the discussions will be available through the investor section of the company’s website at www.oricpharma.com. Replays of the webcasts will be available for 90 days following the events.